<DOC>
	<DOC>NCT00870584</DOC>
	<brief_summary>This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 National Heart, Lung, and Blood Institute (NHBLI) Guidelines</brief_summary>
	<brief_title>Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Total Asthma Control Test (ACT) score of ≤19 plus at least one of the following in the 4 weeks preceding visit 1, on average: Symptoms &gt; 2 days/week Nighttime awakenings ≥1 time/week Shortacting beta2agonist (SABA) use for symptom control &gt;2 days/week forced expiratory volume in 1 second (FEV1) ≤ 80% predicted History of intubation for asthma. An asthma exacerbation requiring treatment with systemic steroids within 4 weeks of screening (Visit 1). Less than 3 months of stable maintenance oral corticosteroid therapy for asthma Other protocoldefined inclusion/exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Asthma; asthma management; asthma impairment ; Xolair ; omalizumab</keyword>
</DOC>